0.5557  -0.034 (-5.81%)		09-21 16:00
Open: 0.56 High: 0.5968 Volume: 81,969		Pre. Close: 0.59 Low: 0.55 Market Cap: 60(M)

Short term
Mid term
Targets	6-month :	0.74	1-year :	0.87
Resists	First :	0.63	Second :	0.74
Pivot price	0.5
Supports	First :	0.51	Second :	0.43
MAs	MA(5) :	0.54	MA(20) :	0.48
	MA(100) :	0.5	MA(250) :	0.52
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	67.2	D(3) :	57.7
RSI	RSI(14): 59.1
52-week	High :	0.82	Low :	0.37

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ IBO ] has closed below upper band by 19.6%. Bollinger Bands are 81.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	0.6 - 0.6	0.6 - 0.6
Low:	0.54 - 0.55	0.55 - 0.55
Close:	0.55 - 0.56	0.56 - 0.56

Houston, Texas-based Impact BioMedical Inc., founded in 2018, focuses on discovering and developing innovative products and therapeutic options for both specialty biopharmaceuticals and consumer healthcare markets. The company features several key technologies: its "Linebacker" platform utilizes small molecule electrophilically enhanced polyphenol compounds with potential applications in treating cancer, inflammatory diseases, and neurological conditions. Additionally, "Laetose" technology, a unique blend of sugar and inositol, is designed to counteract the inflammatory and metabolic responses usually triggered by sugar consumption. Impact BioMedical also creates "functional fragrance formulations," which are a series of fragrances incorporating specialized botanical ingredients for antimicrobial purposes, or as active additives in items like insect repellents, cleaning products, personal care items, and fabrics. Rounding out its offerings is the "Equivir/Equivir G" technology, a distinctive mix of polyphenols that has exhibited antiviral properties, suitable for use in health supplements and medications.

Thu, 17 Sep 2026
Impact BioMedical (IBO) moves toward Zoar merger vote - Stock Titan

Wed, 16 Sep 2026
Impact Biomedical Inc. Announces Filing of F-4 Registration Statement for Proposed Business Combination with Zoar Limited - Quiver Quantitative

Wed, 16 Sep 2026
DSS, Inc. Announces Form F-4 Filing in Connection with Impact Biomedical’s Proposed Business Combination with Zoar Limited - manilatimes.net

Wed, 16 Sep 2026
Impact Biomedical Inc Announces Filing of Form F-4 - GlobeNewswire

Tue, 15 Sep 2026
Impact Biomedical approves 1-for-12.62 reverse stock split ahead of proposed Zoar merger - TradingView

Mon, 14 Sep 2026
CORRECTED — Impact Biomedical Inc (NYSE: IBO) Announces 1 - GlobeNewswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Outperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: AMEX
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	0 (%)
Held by Institutions	0 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.